Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568550 · ClinicalTrials.gov registry record · Phase 2
Pembro With Radiation With or Without Olaparib
A Phase 2 study of Prostate Cancer, sponsored by Zin W Myint.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 2
- Study locations
NCT05568550: Recruiting Phase 2 study of Prostate Cancer, sponsored by Zin W Myint.
NCT05568550 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Zin W Myint. The registered enrollment target is 64 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05568550, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Zin W Myint.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Olaparib
- RADIATION Radiation Therapy
- DRUG Androgen Deprivation Therapy
Study Locations (2)
Kentucky
- University of Kentucky - Lexington
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2029-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05568550
The ClinicalTrials.gov registry entry for NCT05568550 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Zin W Myint, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05568550 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kentucky, Utah.
Frequently Asked Questions
What is clinical trial NCT05568550 about?
NCT05568550 is a clinical study titled "Pembro With Radiation With or Without Olaparib". This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
What is the current status of trial NCT05568550?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-07-27. Estimated completion is 2029-07-02.
What conditions does trial NCT05568550 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05568550?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Olaparib (DRUG), Radiation Therapy (RADIATION), Androgen Deprivation Therapy (DRUG).
Who is sponsoring clinical trial NCT05568550?
This trial is sponsored by Zin W Myint, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05568550 being conducted?
This trial has 2 study locations across Kentucky, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.